Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oligon Therapeutics

Request full access

Multimodal RNA therapeutics silencing multiple disease targets

Montreal, CanadaFounded 2021Biotech & Life Sciences

About Oligon Therapeutics

Oligon Therapeutics is a biotechnology company pioneering a novel class of RNA-based, multi-targeting drugs for oncology, immunology, and other complex diseases. The company was launched on September 23, 2025, with an initial commitment of US $14 million from a consortium of investors including CTI Life Sciences Fund (CTI), the Fonds de solidarité FTQ, and Investissement Québec (IQ). Operations are based in Montreal, Quebec, leveraging the region's life sciences and AI research ecosystem.

The company was founded by Dr. Spyro Mousses, who serves as the CEO. The leadership team also includes Dr. David Bouffard as Chief Operating Officer, Dr. David Azorsa as Chief Scientific Officer, and Dr. Jeff Kiefer as Chief Technology Officer. The company's core technology is the proprietary SeekR™ platform, which engineers and produces self-delivering, multimodal RNA therapeutics. These therapeutics, administered as injectables without special formulations, integrate dual RNA aptamers (oligo-binders) and dual siRNA silencers into a single molecule. This structure allows for unprecedented precision by targeting two specific cell surface receptors, triggering efficient cellular uptake and simultaneously silencing multiple disease-related genes.

Oligon's business model is focused on developing its own pipeline of therapeutic programs and partnering with biopharma and academic collaborators. The current internal pipeline includes programs aimed at cancer immunotherapy by reversing T-cell exhaustion and reprogramming pathogenic T-cell subtypes in immunology and inflammation. Its partnered programs are primarily focused on different types of cancer, with a strategy to expand into additional indications through further industry collaboration. By designing therapies that can deliver siRNA to various cell types beyond the liver, a limitation of previous RNAi drugs, Oligon aims to unlock the full potential of RNA interference in treating complex, multigenic diseases.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
Montreal, Canada
Employees
7
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Drug Development, Genetics and genomics, RNA
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Sep 2025 $14M $56M Invest Quebec · Fonds de solidarité FTQ · CTI Life Sciences ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Oligon Therapeutics website traffic

Latest recorded traffic for Oligon Therapeutics is 1.4K monthly website visits, down 30% over the last three months. Oligon Therapeutics's team grew 250% over the past year.

Latest monthly visits1.4K 3-month web change-30% 1-year team growth+250%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oligon Therapeutics in the Montreal ecosystem

Live from Dealroom

The Oligon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Invest Quebec
  • Fonds de solidarité FTQ
  • CTI Life Sciences
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States50%
🇨🇦 Canada50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oligon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oligon Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.